Biotech IV Monitor

TVTX — Travere Therapeutics Inc.

$5.3B market cap · 4 upcoming readouts tracked

Clinical trial readout dates for Travere Therapeutics Inc., compiled from ClinicalTrials.gov, alongside the SEC filings where results are announced. The next expected readout is March 2027.

Next readoutMarch 2027in ~4 months
Upcoming readouts42 Phase 3
Market cap$5.3B
Cash & investments$472M~9 quarters at last loss rate
Recent 8-K filings1latest 2026-11-02

Upcoming readouts

Phase 2 Sparsentan
Focal Segmental Glomerulosclerosis; Minimal Change Disease · NCT05003986
March 2027
Recruiting
Phase 1/2 Pegtibatinase
Homocystinuria · NCT03406611
July 2027
Recruiting
Phase 3 Pegtibatinase
Homocystinuria · NCT06247085
August 2027
Recruiting
Phase 3 Pegtibatinase
Homocystinuria · NCT06431893
August 2030
Enrolling

Cash position

Travere Therapeutics Inc. reported $472M in cash, cash equivalents and marketable securities at Sep 30, 2026 (10-Q filed 2026-11-02). Its net loss for that quarter was $52M; at that rate the cash would last about 9 quarters. This is a rough guide: net loss includes non-cash items such as stock compensation, and does not count money the company may raise, so its own runway guidance can differ.

Recent SEC filings

8-K Results of Operations — earnings, may carry pipeline updates2026-11-02

Companies working on similar indications

Discussion

No messages yet. If you follow TVTX, you can start the conversation.
Track TVTX in real time
See live implied volatility for TVTX and 106 other biotechs, and get alerted when a readout lands.
🔔 Alert me on TVTX
Contact — questions or corrections about TVTX: dukeupt@gmail.com